Literature DB >> 22718269

Augmented LPS responsiveness in type 1 diabetes-derived osteoclasts.

Dana L Catalfamo1, Nadia L Calderon, Scott W Harden, Heather L Sorenson, Kathleen G Neiva, Shannon M Wallet.   

Abstract

Bone abnormalities are frequent co-morbidities of type 1 diabetes (T1D) and are principally mediated by osteoblasts and osteoclasts which in turn are regulated by immunologic mediators. While decreased skeletal health in T1D involves alterations in osteoblast maturation and function, the effect of altered immune function on osteoclasts in T1D-associated bone and joint pathologies is less understood. Here T1D-associated osteoclast-specific differentiation and function in the presence and absence of inflammatory mediators was characterized utilizing bone marrow-derived osteoclasts (BM-OCs) isolated from non-obese diabetic (NOD) mice, a model for spontaneous autoimmune diabetes with pathology similar to individuals with T1D. Differentiation and osteoclast-mediated bone resorption were evaluated along with cathepsin K, MMP-9, and immune soluble mediator expression. The effect of lipopolysaccharide (LPS), a pro-inflammatory cytokine cocktail, and NOD-derived conditioned supernatants on BM-OC function was also determined. Although NOD BM-OCs cultures contained smaller osteoclasts, they resorbed more bone concomitant with increased cathepsin K, MMP-9, and pro-osteoclastogenic mediator expression. NOD BM-OCs also displayed an inhibition of LPS-induced deactivation that was not a result of soluble mediators produced by NOD BM-OCs, although a pro-inflammatory milieu did enhance NOD BM-OCs bone resorption. Together these data indicate that osteoclasts from a T1D mouse model hyper-respond to RANK-L resulting in excessive bone degradation via enhanced cathepsin K and MMP-9 secretion concomitant with an increased expression of pro-osteoclastic soluble mediators. Our data also suggest that inhibition of LPS-induced deactivation in NOD-derived BM-OC cultures is most likely due to NOD osteoclast responsiveness rather than LPS-induced expression of soluble mediators.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22718269      PMCID: PMC3470828          DOI: 10.1002/jcp.24138

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  65 in total

1.  Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function.

Authors:  Brian Poligone; Donald J Weaver; Pradip Sen; Albert S Baldwin; Roland Tisch
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation.

Authors:  Huafei Lu; Douglas Kraut; Louis C Gerstenfeld; Dana T Graves
Journal:  Endocrinology       Date:  2003-01       Impact factor: 4.736

3.  Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase.

Authors:  D J Weaver; B Poligone; T Bui; U M Abdel-Motal; A S Baldwin; R Tisch
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  Molecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis.

Authors:  K E Lawlor; I K Campbell; K O'Donnell; L Wu; I P Wicks
Journal:  Arthritis Rheum       Date:  2001-02

5.  Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.

Authors:  W Zou; I Hakim; K Tschoep; S Endres; Z Bar-Shavit
Journal:  J Cell Biochem       Date:  2001 Jun 26-Jul 25       Impact factor: 4.429

6.  Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B.

Authors:  David Cappellen; Ngoc-Hong Luong-Nguyen; Sandrine Bongiovanni; Olivier Grenet; Christoph Wanke; Mira Susa
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

7.  NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages.

Authors:  Pradip Sen; Sandip Bhattacharyya; Mark Wallet; Carmen P Wong; Brian Poligone; Maitreyee Sen; Albert S Baldwin; Roland Tisch
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Stimulation by toll-like receptors inhibits osteoclast differentiation.

Authors:  Masamichi Takami; Nacksung Kim; Jaerang Rho; Yongwon Choi
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

9.  A role for advanced glycation end products in diminished bone healing in type 1 diabetes.

Authors:  Ronaldo B Santana; Lei Xu; Hermik Babakhanlou Chase; Salomon Amar; Dana T Graves; Philip C Trackman
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

10.  Glucose-dependent regulation of osteoclast H(+)-ATPase expression: potential role of p38 MAP-kinase.

Authors:  Kirsten I Larsen; Marina L Falany; Larissa V Ponomareva; Wei Wang; John P Williams
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

View more
  4 in total

Review 1.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 2.  Mouse models of type 1 diabetes and their use in skeletal research.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-24       Impact factor: 3.626

Review 3.  Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.

Authors:  Tayyab S Khan; Lisa-Ann Fraser
Journal:  J Osteoporos       Date:  2015-03-22

4.  Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus.

Authors:  Nick Hildebrandt; Juliane Colditz; Lorenz C Hofbauer; Martina Rauner; Caio Dutra; Paula Goes; Juliane Salbach-Hirsch; Sylvia Thiele
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.